Identification of the likely translational start of Mycobacterium tuberculosis GyrB

BMC Research Notes

Anthony Maxwell³  Tanya Parish⁴  Amanda C Brown¹  Shantanu Karkare² 

[1] Present address: Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke OX5 1PF, UK;Present address: Novartis Institute of Biomedical Research, Basel 4056, Switzerland;Department of Biological Chemistry, John Innes Centre Norwich Research Park, Norwich NR4 7UH, UK;Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London E1 2AT, UK

关键词: Mycobacterium tuberculosis;    Topoisomerase;    Gyrase;   

Others  :  1142156
DOI  :  10.1186/1756-0500-6-274

 received in 2013-02-14, accepted in 2013-07-08,  发布年份 2013

【 摘 要 】

Background

Bacterial DNA gyrase is a validated target for antibacterial chemotherapy. It consists of two subunits, GyrA and GyrB, which form an A₂B₂ complex in the active enzyme. Sequence alignment of Mycobacterium tuberculosis GyrB with other bacterial GyrBs predicts the presence of 40 potential additional amino acids at the GyrB N-terminus. There are discrepancies between the M. tuberculosis GyrB sequences retrieved from different databases, including sequences annotated with or without the additional 40 amino acids. This has resulted in differences in the GyrB sequence numbering that has led to the reporting of previously known fluoroquinolone-resistance mutations as novel mutations.

Findings

We have expressed M. tuberculosis GyrB with and without the extra 40 amino acids in Escherichia coli and shown that both can be produced as soluble, active proteins. Supercoiling and other assays of the two proteins show no differences, suggesting that the additional 40 amino acids have no effect on the enzyme in vitro. RT-PCR analysis of M. tuberculosis mRNA shows that transcripts that could yield both the longer and shorter protein are present. However, promoter analysis showed that only the promoter elements leading to the shorter GyrB (lacking the additional 40 amino acids) had significant activity.

Conclusion

We conclude that the most probable translational start codon for M. tuberculosis GyrB is GTG (Val) which results in translation of a protein of 674 amino acids (74 kDa).

【 授权许可】

   
2013 Karkare et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Collin F, Karkare S, Maxwell A: Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. Appl Microbiol Biotechnol 2011, 92(3):479-497.
• [2]Bates AD, Maxwell A: DNA Topology. Oxford: Oxford University Press; 2005.
• [3]Schoeffler AJ, Berger JM: DNA topoisomerases: harnessing and constraining energy to govern chromosome topology. Q Rev Biophys 2008, 41(1):41-101.
• [4]Pommier Y, Leo E, Zhang H, Marchand C: DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010, 17(5):421-433.
• [5]Tse-Dinh YC: Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases. Infect Disord Drug Targets 2007, 7(1):3-9.
• [6]Nollmann M, Crisona NJ, Arimondo PB: Thirty years of Escherichia coli DNA gyrase: from in vivo function to single-molecule mechanism. Biochimie 2007, 89(4):490-499.
• [7]Young D, Stark J, Kirschner D: Systems biology of persistent infection: tuberculosis as a case study. Nat Rev Microbiol 2008, 6(7):520-528.
• [8]Takiff H, Guerrero E: Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob Agents Chemother 2011, 55(12):5421-5429.
• [9]Aubry A, Fisher LM, Jarlier V, Cambau E: First functional characterization of a singly expressed bacterial type II topoisomerase: the enzyme from Mycobacterium tuberculosis. Biochem Biophys Res Commun 2006, 348(1):158-165.
• [10]Unniraman S, Chatterji M, Nagaraja V: DNA gyrase genes in Mycobacterium tuberculosis: a single operon driven by multiple promoters. J Bacteriol 2002, 184(19):5449-5456.
• [11]Camus JC, Pryor MJ, Medigue C, Cole ST: Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology 2002, 148(Pt 10):2967-2973.
• [12]Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A: A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 2012, 67(4):819-831.
• [13]Karkare S, Yousafzai F, Mitchenall LA, Maxwell A: The role of Ca2+ in the activity of Mycobacterium tuberculosis DNA gyrase. Nucleic Acids Res 2012, 40(19):9774-9787.
• [14]Rustad TR, Harrell MI, Liao R, Sherman DR: The enduring hypoxic response of Mycobacterium tuberculosis. PLoS One 2008, 3(1):e1502.
• [15]Brown AC, Eberl M, Crick DC, Jomaa H, Parish T: The nonmevalonate pathway of isoprenoid biosynthesis in Mycobacterium tuberculosis is essential and transcriptionally regulated by Dxs. J Bacteriol 2010, 192(9):2424-2433.
• [16]Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE 3rd, et al.: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998, 393(6685):537-544.
• [17]Dussurget O, Timm J, Gomez M, Gold B, Yu S, Sabol SZ, Holmes RK, Jacobs WR, Smith I: Transcriptional control of the iron-responsivefxbA gene by the mycobacterial regulator IdeR. J Bacteriol 1999, 181(11):3402-3408.
• [18]Carroll P, James J: Assaying promoter activity using LacZ and GFP as reporters. Methods Mol Biol 2009, 465:265-277.
• [19]Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, et al.: Clustal W and Clustal X version 2.0. Bioinformatics 2007, 23(21):2947-2948.